Access : Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas : Modern Pathology

Access : Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas : Modern Pathology

Myasthenia Gravis. Myasthenia gravis (MG) was first described by Thomas Willis in 1672. It is an acquired autoimmune disease with antibodies against the nicotinic acetylcholine receptor (AChR) at the neuromuscular junction or muscle-specific tyrosine kinase (MuSK). This leads to muscular weakness with easy 'fatiguability', which is worse on exercise and improves with rest. (read more here)

Myasthenia Gravis. Myasthenia gravis (MG) was first described by Thomas Willis in 1672. It is an acquired autoimmune disease with antibodies against the nicotinic acetylcholine receptor (AChR) at the neuromuscular junction or muscle-specific tyrosine kinase (MuSK). This leads to muscular weakness with easy 'fatiguability', which is worse on exercise and improves with rest. (read more here)

tyrosine kinase receptor | insulin receptor receptor tyrosine kinase school jam biomedical ...

tyrosine kinase receptor | insulin receptor receptor tyrosine kinase school jam biomedical ...

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients: Cancer Cell

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients: Cancer Cell

Sunitinib (Sutent) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Sunitinib was the first cancer drug simultaneously approved for two different indications. Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs).  These include all PDGF-Rs and VEGFRs, which play a role in both tumor angiogenesis and tumor cell proliferation.

Sunitinib (Sutent) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Sunitinib was the first cancer drug simultaneously approved for two different indications. Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs). These include all PDGF-Rs and VEGFRs, which play a role in both tumor angiogenesis and tumor cell proliferation.

Receptor Tyrosine Kinase animation. Binding of insulin ligand will cause monomers to become dimers. Then, the (many) tyrosine(s) will auto-phosphorylate. This creates another conformational change that allows it to interact with an "adapter protein" which then indirectly binds  with a G-protein.   The tyrosine kinase can lead to multiple cellular responses from just ONE signal.

Receptor Tyrosine Kinase animation. Binding of insulin ligand will cause monomers to become dimers. Then, the (many) tyrosine(s) will auto-phosphorylate. This creates another conformational change that allows it to interact with an "adapter protein" which then indirectly binds with a G-protein. The tyrosine kinase can lead to multiple cellular responses from just ONE signal.

Pinterest
Search